Kiniksa Pharmaceuticals International, plc
KNSA
$20.21
-$0.325-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 46.93% | 67.37% | 51.99% | 65.18% | 34.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.93% | 67.37% | 51.99% | 65.18% | 34.76% |
| Cost of Revenue | 149.16% | 87.19% | 95.23% | 104.80% | 86.36% |
| Gross Profit | -0.74% | 54.50% | 33.15% | 46.80% | 19.35% |
| SG&A Expenses | 10.33% | 34.61% | 45.31% | 33.18% | 35.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.24% | 56.30% | 45.72% | 61.91% | 49.21% |
| Operating Income | -23,925.93% | 11.61% | 96.29% | -47.75% | -98.66% |
| Income Before Tax | -793.02% | 15.27% | 285.96% | -52.46% | -64.19% |
| Income Tax Expenses | 64.49% | 2.54% | 138.32% | 17.96% | -1,057.44% |
| Earnings from Continuing Operations | -135.22% | 8.39% | -126.10% | -44.29% | 465.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -135.22% | 8.39% | -126.10% | -44.29% | 465.73% |
| EBIT | -23,925.93% | 11.61% | 96.29% | -47.75% | -98.66% |
| EBITDA | -3,143.32% | 10.32% | 112.26% | -51.66% | -90.66% |
| EPS Basic | -134.27% | 10.33% | -125.69% | -42.47% | 459.44% |
| Normalized Basic EPS | -772.94% | 17.17% | 282.88% | -50.54% | -64.50% |
| EPS Diluted | -134.96% | 10.33% | -128.57% | -42.47% | 548.52% |
| Normalized Diluted EPS | -795.26% | 17.17% | 287.96% | -50.54% | -64.77% |
| Average Basic Shares Outstanding | 2.77% | 2.20% | 1.55% | 1.26% | 1.10% |
| Average Diluted Shares Outstanding | -0.47% | 2.20% | -0.88% | 1.26% | 1.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |